Latest Breaking News On - Constellation pharmaceutical - Page 1 : comparemela.com

MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retiremen

DGAP-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters 31.08.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, August 31, 2.

United statesUnited kingdomThomas biegiTim demuthJulia neugebauerEamonn nolanJean paul kressMarc cluzelDevelopment officerConstellation pharmaceutical researchXencor incMerck coDistribution servicesLudwig maximilian universityEuropean unionPieris pharmaceuticals inc

MorphoSys AG: MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters

Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Malte Peters

United statesUnited kingdomThomas biegiTim demuthJulia neugebauerEamonn nolanJean paul kressMarc cluzelDevelopment officerConstellation pharmaceutical researchXencor incMerck coLudwig maximilian universityEuropean unionClinical developmentPieris pharmaceuticals inc

MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters

MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomThomas biegiTim demuthJulia neugebauerEamonn nolanJean paul kressMarc cluzelDevelopment officerConstellation pharmaceutical researchXencor incMerck coLudwig maximilian universityEuropean unionPieris pharmaceuticals incClinical development

Momelotinib Hits the Mark for Deadly Bone Marrow Cancer

The investigational drug has shown benefits in myelofibrosis in a new phase 3 trial with a new sponsor, which plans to apply for FDA approval.

United statesJolla pharmaRuben mesaGabriela hobbsGenentech incyteMays cancer centerAmerican society of clinical oncologyConstellation pharmaceuticalsDrug administrationHarvard medical schoolSierra oncologyAmerican societyManderson cancerConstellation pharmaceutical

Medical News Forecast for December 6-12 | Physician s Weekly

Medical News Forecast for December 6-12 | Physician s Weekly
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioSanofi sarclisaRoche genentechLynne petersonAbbvie venclextaAstrazeneca calquenceRoche tecentriqMorphosy monjuviGilead sciences kite yescartaAmerican epilepsy societyRenal drugs advisory committeeInternational symposiumNeurological devices advisory committeeJaguar health napo pharmaceutical mytesiAmerican society of hematology